Handelen Black Diamond Therapeutics, Inc. - BDTX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.0672 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Black Diamond Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 2.3266 |
| Open* | 2.3465 |
| 1-Jaarlijkse Verandering* | 33.32% |
| Dagelijks bereik* | 2.3465 - 2.4963 |
| 52 wekelijks bereik | 1.18-4.08 |
| Weekgemiddelde volume (10 dagen) | 74.14K |
| Gemiddeld volume (3 maanden) | 1.74M |
| Marktkapitalisatie | 85.44M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 36.51M |
| Omzet | N/A |
| EPS | -2.38 |
| Dividend (opbrengst %) | N/A |
| Beta | 1.89 |
| Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 5, 2023 | 2.4564 | 0.1998 | 8.85% | 2.2566 | 2.5063 | 2.2366 |
| Jun 2, 2023 | 2.3266 | 0.1399 | 6.40% | 2.1867 | 2.3665 | 2.0969 |
| Jun 1, 2023 | 2.1368 | 0.3295 | 18.23% | 1.8073 | 2.1668 | 1.7973 |
| May 31, 2023 | 1.8373 | 0.0300 | 1.66% | 1.8073 | 1.8572 | 1.7973 |
| May 30, 2023 | 1.8572 | 0.0999 | 5.68% | 1.7573 | 1.8772 | 1.7573 |
| May 26, 2023 | 1.7673 | 0.0699 | 4.12% | 1.6974 | 1.7774 | 1.6575 |
| May 25, 2023 | 1.7274 | 0.0699 | 4.22% | 1.6575 | 1.7574 | 1.6575 |
| May 24, 2023 | 1.6974 | 0.0100 | 0.59% | 1.6874 | 1.7374 | 1.6375 |
| May 23, 2023 | 1.6775 | -0.1298 | -7.18% | 1.8073 | 1.8672 | 1.6774 |
| May 22, 2023 | 1.8373 | 0.0899 | 5.14% | 1.7474 | 1.8772 | 1.7474 |
| May 19, 2023 | 1.7773 | 0.0699 | 4.09% | 1.7074 | 1.7873 | 1.6175 |
| May 18, 2023 | 1.5976 | -0.0998 | -5.88% | 1.6974 | 1.6975 | 1.5576 |
| May 17, 2023 | 1.7074 | -0.0400 | -2.29% | 1.7474 | 1.7674 | 1.6774 |
| May 16, 2023 | 1.7673 | -0.1198 | -6.35% | 1.8871 | 1.9171 | 1.7673 |
| May 15, 2023 | 1.9171 | 0.1198 | 6.67% | 1.7973 | 1.9271 | 1.7573 |
| May 12, 2023 | 1.8672 | -0.0399 | -2.09% | 1.9071 | 1.9071 | 1.8073 |
| May 11, 2023 | 1.9171 | 0.1098 | 6.08% | 1.8073 | 1.9970 | 1.7973 |
| May 10, 2023 | 1.8472 | 0.0499 | 2.78% | 1.7973 | 1.8972 | 1.7973 |
| May 9, 2023 | 1.8173 | 0.0400 | 2.25% | 1.7773 | 1.8173 | 1.6575 |
| May 8, 2023 | 1.9072 | 0.0300 | 1.60% | 1.8772 | 1.9371 | 1.8572 |
Black Diamond Therapeutics, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Friday, June 9, 2023 | ||
| Tijd (UTC) (UTC) 16:45 | Land US
| Evenement Black Diamond Therapeutics Inc at Jefferies Healthcare Conference Black Diamond Therapeutics Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q2 2023 Black Diamond Therapeutics Inc Earnings Release Q2 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Tijd (UTC) (UTC) 13:30 | Land US
| Evenement Q3 2023 Black Diamond Therapeutics Inc Earnings Release Q3 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 92.828 | 126.872 | 69.57 | 29.332 | 8.904 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 28.391 | 30.043 | 21.361 | 7.579 | 1.954 |
| Onderzoek & Ontwikkeling | 64.437 | 96.829 | 48.209 | 21.753 | 6.95 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | ||||
| Bedrijfsresultaat | -92.828 | -126.872 | -69.57 | -29.332 | -8.904 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.219 | 3.464 | 4.041 | -5.932 | -0.011 |
| Overige, Netto | -0.354 | -2.188 | -1.725 | 0.006 | -0.016 |
| Netto inkomen voor belastingen | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Netto inkomen na belastingen | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Netto inkomen voor extra. Posten | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Netto inkomen | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Verwaterd Netto Inkomen | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Verwaterd Gewogen Gemiddelde Aandelen | 36.3256 | 36.189 | 32.9071 | 32.6364 | 32.6364 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.50977 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Verwaterde Genormaliseerde Winst per Aandeel | -2.57122 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
| Gain (Loss) on Sale of Assets | 2.232 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 21.561 | 21.852 | 22.124 | 23.173 | 25.679 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 6.808 | 7.243 | 6.277 | 6.978 | 7.893 |
| Onderzoek & Ontwikkeling | 14.753 | 14.609 | 15.847 | 16.195 | 17.786 |
| Bedrijfsresultaat | -21.561 | -21.852 | -22.124 | -23.173 | -25.679 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.622 | -1.573 | 0.562 | 0.386 | 0.406 |
| Overige, Netto | 0.064 | 0.115 | -0.092 | -0.143 | -0.234 |
| Netto inkomen voor belastingen | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Netto inkomen na belastingen | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Netto inkomen voor extra. Posten | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Netto inkomen | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Verwaterd Netto Inkomen | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Verwaterd Gewogen Gemiddelde Aandelen | 36.4839 | 36.3902 | 36.3462 | 36.2939 | 36.2713 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.57217 | -0.57922 | -0.59577 | -0.63179 | -0.70323 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.57217 | -0.64056 | -0.59577 | -0.63179 | -0.70323 |
| Gain (Loss) on Sale of Assets | 2.232 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 127.706 | 215.703 | 319.554 | 155.714 | 51.684 |
| Geldmiddelen en kortetermijnbeleggingen | 122.807 | 209.786 | 315.067 | 154.666 | 51.66 |
| Geldmiddelen & Equivalenten | 34.315 | 65.799 | 34.605 | 154.666 | 51.66 |
| Prepaid Expenses | 4.899 | 5.917 | 4.487 | 1.048 | 0.024 |
| Total Assets | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
| Property/Plant/Equipment, Total - Net | 27.381 | 30.74 | 8.787 | 0.164 | 0.134 |
| Property/Plant/Equipment, Total - Gross | 28.131 | 31.109 | 8.951 | 0.276 | 0.234 |
| Accumulated Depreciation, Total | -0.75 | -0.369 | -0.164 | -0.112 | -0.1 |
| Other Long Term Assets, Total | 1.168 | 1.239 | 1.329 | 2.417 | 0.008 |
| Total Current Liabilities | 15.261 | 23.642 | 14.218 | 4.863 | 2.575 |
| Accounts Payable | 1.877 | 4.107 | 2.538 | 1.964 | 0.416 |
| Accrued Expenses | 13.384 | 19.535 | 11.68 | 2.899 | 0.452 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 1.707 | |||
| Total Liabilities | 40.56 | 51.782 | 21.912 | 4.879 | 6.598 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 25.299 | 28.14 | 7.694 | 0.016 | 4.023 |
| Total Equity | 115.695 | 195.9 | 307.758 | 153.416 | 45.228 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 60.77 | ||
| Common Stock | 0.005 | 0.005 | 0.005 | 0.001 | 0.001 |
| Additional Paid-In Capital | 452.503 | 440.129 | 425.363 | 3.812 | 0.169 |
| Retained Earnings (Accumulated Deficit) | -334.989 | -243.82 | -118.224 | -50.97 | -15.712 |
| Total Liabilities & Shareholders’ Equity | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
| Total Common Shares Outstanding | 36.4343 | 36.2346 | 36.0784 | 32.6364 | 32.6364 |
| Redeemable Preferred Stock | 0 | 0 | 200.573 | ||
| Korte Termijn Investeringen | 88.492 | 143.987 | 280.462 | ||
| Other Equity, Total | -0.414 | 0.614 | |||
| Unrealized Gain (Loss) | -1.824 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 107.977 | 127.706 | 150.978 | 168.558 | 188.304 |
| Geldmiddelen en kortetermijnbeleggingen | 103.366 | 122.807 | 144.181 | 160.89 | 179.739 |
| Geldmiddelen & Equivalenten | 39.141 | 34.315 | 53.96 | 55.877 | 54.081 |
| Korte Termijn Investeringen | 64.225 | 88.492 | 90.221 | 105.013 | 125.658 |
| Prepaid Expenses | 4.611 | 4.899 | 6.797 | 7.668 | 8.565 |
| Total Assets | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
| Property/Plant/Equipment, Total - Net | 26.437 | 27.381 | 28.27 | 29.098 | 29.945 |
| Property/Plant/Equipment, Total - Gross | 27.282 | 28.131 | 28.98 | 29.681 | 30.439 |
| Accumulated Depreciation, Total | -0.845 | -0.75 | -0.71 | -0.583 | -0.494 |
| Other Long Term Assets, Total | 1.168 | 1.168 | 1.168 | 1.178 | 1.233 |
| Total Current Liabilities | 12.847 | 15.261 | 21.143 | 19.706 | 19.469 |
| Accounts Payable | 3.046 | 1.877 | 5.76 | 2.222 | 1.883 |
| Accrued Expenses | 9.801 | 13.384 | 15.383 | 17.484 | 17.586 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 37.392 | 40.56 | 47.185 | 46.463 | 46.922 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 24.545 | 25.299 | 26.042 | 26.757 | 27.453 |
| Total Equity | 98.19 | 115.695 | 133.231 | 152.371 | 172.56 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
| Additional Paid-In Capital | 455.225 | 452.503 | 449.625 | 446.909 | 443.657 |
| Retained Earnings (Accumulated Deficit) | -355.864 | -334.989 | -313.911 | -292.257 | -269.327 |
| Other Equity, Total | -1.176 | -1.824 | -2.488 | -2.286 | -1.775 |
| Total Liabilities & Shareholders’ Equity | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
| Total Common Shares Outstanding | 36.512 | 36.4343 | 36.3662 | 36.3157 | 36.2876 |
| Redeemable Preferred Stock |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Geldmiddelen uit Operationele Activiteiten | -85.082 | -100.148 | -52.146 | -24.674 | -8.454 |
| Geldmiddelen uit Operationele Activiteiten | 0.508 | 0.205 | 0.052 | 0.047 | 0.044 |
| Niet-Geldelijke Posten | 15.48 | 18.223 | 10.014 | 10.074 | 0.079 |
| Veranderingen in het Operationeel Kapitaal | -9.901 | 7.02 | 5.042 | 0.463 | 0.354 |
| Geldmiddelen uit Investeringsactiviteiten | 53.366 | 130.613 | -281.691 | -0.021 | -0.076 |
| Kapitaaluitgaven | -0.192 | -2.71 | -0.142 | -0.021 | -0.076 |
| Overige Cash Flow investeringsposten, Totaal | 53.558 | 133.323 | -281.549 | 0 | |
| Geldmiddelen uit Financieringsactiviteiten | 0.177 | 0.729 | 214.944 | 127.756 | 52.312 |
| Financiering van Cash Flow Posten | 0 | -1.743 | 0 | ||
| Uitgifte (Aflossing) van aandelen, netto | 0.177 | 0.729 | 214.944 | 129.499 | 52.312 |
| Uitgifte (Aflossing) van Schulden, Netto | 0 | ||||
| Nettowijziging in Geldmiddelen | -31.539 | 31.194 | -118.893 | 103.061 | 43.782 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -20.875 | -91.169 | -70.091 | -48.437 | -25.507 |
| Cash From Operating Activities | -20.031 | -85.082 | -63.143 | -46.667 | -28.6 |
| Cash From Operating Activities | 0.122 | 0.508 | 0.382 | 0.253 | 0.125 |
| Non-Cash Items | 3.507 | 15.48 | 11.804 | 8.366 | 4.293 |
| Changes in Working Capital | -2.785 | -9.901 | -5.238 | -6.849 | -7.511 |
| Cash From Investing Activities | 24.806 | 53.366 | 51.044 | 36.537 | 16.729 |
| Capital Expenditures | 0 | -0.192 | -0.192 | -0.2 | -0.007 |
| Other Investing Cash Flow Items, Total | 24.806 | 53.558 | 51.236 | 36.737 | 16.736 |
| Cash From Financing Activities | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
| Issuance (Retirement) of Stock, Net | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
| Net Change in Cash | 4.826 | -31.539 | -11.894 | -9.977 | -11.718 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Versant Ventures | Venture Capital | 17.6634 | 6449348 | 0 | 2023-03-15 | LOW |
| Bellevue Asset Management AG | Investment Advisor | 14.778 | 5395839 | -5000 | 2023-03-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 9.4454 | 3448757 | 0 | 2023-03-31 | LOW |
| RA Capital Management, LP | Hedge Fund | 7.0932 | 2589904 | 0 | 2023-03-31 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 5.5183 | 2014858 | 0 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 4.5095 | 1646517 | 0 | 2023-03-31 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 3.2621 | 1191094 | 908963 | 2023-03-31 | LOW |
| Epstein (David M) | Individual Investor | 2.5703 | 938479 | 0 | 2023-03-15 | LOW |
| Millennium Management LLC | Hedge Fund | 2.1269 | 776594 | 252037 | 2023-03-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0749 | 757585 | 0 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 1.5276 | 557771 | -216027 | 2023-03-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4344 | 523719 | -127676 | 2023-03-31 | LOW |
| Verition Fund Management LLC | Hedge Fund | 0.943 | 344307 | 344307 | 2023-03-31 | HIGH |
| Newtyn Management, LLC | Hedge Fund | 0.8397 | 306609 | -8391 | 2023-03-31 | MED |
| Two Sigma Investments, LP | Hedge Fund | 0.7769 | 283654 | -72510 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7406 | 270428 | 5138 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.5957 | 217500 | -3113 | 2023-03-31 | HIGH |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.5023 | 183398 | -102283 | 2023-03-31 | LOW |
| BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.3968 | 144888 | 0 | 2023-03-31 | LOW |
| Tekla Capital Management LLC | Investment Advisor | 0.3615 | 131990 | 0 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Black Diamond Therapeutics, Inc. Company profile
Over Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is een bedrijf dat zich bezighoudt met oncologische precisiegeneeskunde. Het bedrijf is gericht op de ontdekking en ontwikkeling van kleine molecule, MasterKey therapieën. Het bouwt aan een pijplijn van kleine molecule kinase-inhibitoren die gericht zijn tegen een reeks van driver mutaties in kanker. Haar technologieplatform, Mutation-Allostery-Pharmacology (MAP), is ontworpen om genetische sequencinggegevens op populatieniveau te analyseren om oncogene mutaties te ontdekken die kanker in tumortypes bevorderen. De belangrijkste productkandidaat, BDTX-189, is ontworpen als een oraal beschikbare, onomkeerbare kleine molecule-remmer die een spectrum van 48 niet-kanonieke en canonieke driver-mutaties van de ErbB-kinases epidermale groeifactor receptor (EGFR) & HER2 aanpakt. BDTX-1535 is een hersenpenetrerende remmer die een spectrum van EGFR-mutaties aanpakt, waaronder allosterische en canonieke mutaties. Het bedrijf heeft ook programma's in een vroeg stadium, zoals B-Raf Proto-Oncogene (BRAF), en fibroblast groeifactor receptor (FGFR).
| Industry: | Bio Therapeutic Drugs |
One Main Street, 14th Floor
CAMBRIDGE
MASSACHUSETTS 02142
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen